 • On Election Day, five U.S. states passed a total of six ballot initiatives for legalized cannabis programs.
• Four states (Arizona, New Jersey, Montana, and South Dakota) adopted adult-use measures; Mississippi and South Dakota both legalized cannabis for medical use. • South Dakota made history as the first state to adopt both recreational and medical cannabis programs through the same ballot. • Including the new states’ revenues, the total U.S. legal market projects to reach $38.3 billion by 2025. • New Jersey’s legalization of a recreational market will be catalytic for expansion and normalization of cannabis programs in the Northeast and East Coast. • Approximately 234 million people—a majority of Americans—will be living with legal access to either a medical or an adult-use market.
0 Comments
Are you wondering what the marijuana laws are in your state?
disa.com/map-of-marijuana-legality-by-state Marijuana laws are changing at a rapid pace across all 50 states, making things a bit confusing at times. In order to keep up with the ever-changing laws, DISA has provided this interactive map for information on legalization, medical use, recreational use, and anything in between. This marijuana legalization map clearly defines the laws in each state and remains up-to-date with the latest changes on a monthly basis. It’s important to understand and respect the rules that vary across the U.S. regarding marijuana use, and whether you’re a visiting tourist, or a resident the following information will help you steer clear of any misunderstandings or trouble. Scroll over each state to learn more about their individual legalization laws. Last Updated: October 2020 Note: State status reflects current laws at time of update, not pending legislation or future dates upon which marijuana becomes available medicinally or recreationally. * Enactment is pending until future date. Start A Drug Testing PolicyEducating your employees and enforcing a consistent drug testing policy is crucial to keeping your workplace safe. Talk with a DISA representative today and get the information you need to start a drug testing policy at your company. CONTACT US
Legal Status Medicinal Decriminalized State Laws Alabama Fully Illegal No No View State Laws Alaska Fully Legal Yes Yes View State Laws Arizona Mixed Yes No View State Laws Arkansas Mixed Yes No View State Laws California Fully Legal Yes Yes View State Laws Colorado Fully Legal Yes Yes View State Laws Connecticut Mixed Yes Yes View State Laws Delaware Mixed Yes Yes View State Laws District of Columbia Fully Legal Yes Yes View State Laws Florida Mixed Yes No View State Laws Georgia Mixed CBD Oil Only No View State Laws Hawaii Mixed Yes Yes View State Laws Idaho Fully Illegal No No View State Laws Illinois Fully Legal Yes Yes View State Laws Indiana Mixed CBD Oil Only No View State Laws Iowa Mixed CBD Oil Only No View State Laws Kansas Fully Illegal No No View State Laws Kentucky Mixed CBD Oil Only No View State Laws Louisiana Mixed Yes No View State Laws Maine Fully Legal Yes Yes View State Laws Maryland Mixed Yes Yes View State Laws Massachusetts Fully Legal Yes Yes View State Laws Michigan Fully Legal Yes Yes View State Laws Minnesota Mixed Yes Yes View State Laws Mississippi Fully Illegal No Yes View State Laws Missouri Mixed Yes Yes View State Laws Montana Mixed Yes No View State Laws Nebraska Fully Illegal No Yes View State Laws Nevada Fully Legal Yes Yes View State Laws New Hampshire Mixed Yes Yes View State Laws New Jersey Mixed Yes No View State Laws New Mexico Mixed Yes Yes View State Laws New York Mixed Yes Yes View State Laws North Carolina Fully Illegal No Yes View State Laws North Dakota Mixed Yes Yes View State Laws Ohio Mixed Yes Yes View State Laws Oklahoma Mixed Yes No View State Laws Oregon Fully Legal Yes Yes View State Laws Pennsylvania Mixed European cannabis market, rich with potential, worth 240 million euros in 2019, new report shows10/11/2020 European cannabis market, rich with potential, worth 240 million euros in 2019, new report showsPublished May 6, 2020 | By Matt Lamers
Europe’s legal medical cannabis market might one day eclipse North America’s, but in 2019 the market was worth roughly 240 million euros ($260 million) – meaning the continent is still far from reaching its potential. That is one of the critical takeaways from Marijuana Business Daily’s updated – and free – report, “Medical Cannabis in Europe: The Markets & Opportunities.” “This report provides industry leaders and investors interested in the European markets with a realistic estimate of current market sizes and a detailed analysis of the countries where the most opportunities exist,” wrote the author of the report, MJBizDaily International Analyst Alfredo Pascual. Pascual believes executives will benefit from an honest picture of the market as it exists today, instead of relying mostly on wildly speculative projections of what could occur years into the future. “Most cannabis companies don’t have years of cash available to spend without generating much revenue until those future multibillion markets materialize,” he said in an interview. “While the long-term expectation of Europe being a massive medical – and, eventually, recreational – cannabis industry continues to show promise, this report highlights the reality of the market today, including the actual sales and the regulatory frameworks that exist in the main European markets,” Pascual wrote in the report. “Medical Cannabis in Europe” lends credence to executives who are growing their businesses as the European market evolves. That is another critical takeaway from the report, Pascual said. “Businesses can only operate within the boundaries of a jurisdiction’s laws and regulations,” he said. “In many cases in Europe, those laws and regulations are in an infantile stage. “The risk some businesses face is they’re building facilities before laws and regulations are clear and before functional markets develop.” Marijuana Business Daily estimates total sales of medical cannabis in Europe in 2019 ranged from 230 million to 250 million euros, with the report noting that accurate estimates are complex because of a lack of official data in several of the main markets and no harmonized definitions of medical cannabis across the continent. Roughly half the retail value was accounted for in the markup that pharmacies add before dispensing the products in countries such as Germany and Italy. More takeaways from “Medical Cannabis in Europe”:
<https://harrisbricken.com/cannalawblog/arizona-cannabis-legalization-guide-
prop-207/> Arizona Cannabis Legalization Guide (Prop 207) <https://harrisbricken.com/cannalawcategory/medical-marijuana/> MEDICAL MARIJUANA, <https://harrisbricken.com/cannalawcategory/recreational-marijuana/> RECREATIONAL MARIJUANA, <https://harrisbricken.com/cannalawcategory/states/> STATES OCTOBER 4TH, 2020 <https://harrisbricken.com/blog/author/cannalawblog/> by <https://harrisbricken.com/blog/author/cannalawblog/> Canna Law Blog This November 2020 election, cannabis legalization initiatives will appear on the ballots of five states: Arizona, Mississippi, Montana, New Jersey and South Dakota. Every Sunday until November 3, Canna Law Blog will publish a post centered on one of these state ballot initiatives, and the current laws surrounding cannabis in that state. Today is the first post, in which we discuss the ballot initiative in Arizona, Proposition 203, or the Marijuana Legalization Initiative. What are current Arizona's laws surrounding cannabis? In 2010, Arizona legalized medical cannabis through the passage of the ballot measure Proposition 203, known as the <https://ballotpedia.org/Arizona_Medical_Marijuana_Question,_Proposition_203 _(2010)> Arizona Medical Marijuana Initiative. The enacting statute, known as the Arizona Medical Marijuana Act (AMMA), allows Arizona residents with medical conditions to possess certain amounts of cannabis for medical use, with qualified patients and caregivers allowed to purchase cannabis from specific clinics. This law charged the Arizona Department of Health Services (ADHS) with regulating the sale and use of medical cannabis. Additionally, the AMMA protects patients who use medical cannabis from state arrest and prosecution as well as discrimination from employers. The AMMA was controversial, barely scraping into law with 50.1% of the vote. Many political action groups and politicians lobbied against and opposed the ballot measure, including then-Governor of Arizona Jan Brewer (R). Since the passage of the law, the ADHS and the Arizona State Congress have limited the scope of the AMMA. In March of 2011, the ADHS laid out licensing regulations for patients as well as rules about which medical conditions qualified a patient for medical cannabis use, listing only 14 qualifying medical conditions in total. According to the Washington Post, only around 20,000 Arizona residents qualified for medical cannabis use under these regulations. Additionally, the ADHS regulations prohibited qualified patients from smoking cannabis in public spaces. In 2012, the Arizona State Congress signed a bill into law which prohibited the use or possession of medical cannabis on any college campus in Arizona. In 2018, however, the Arizona Supreme Court, <https://www.courthousenews.com/campus-pot-ban-in-arizona-ruled-unconstituti onal/> struck down this law as unconstitutional on the grounds that the legislature could not prove that criminalizing medical cannabis on college campuses would preserve federal funding. What's the ballot initiative this coming election? This November 2020, Arizonians will vote on the <https://ballotpedia.org/Arizona_Proposition_207,_Marijuana_Legalization_Ini tiative_(2020)#cite_note-text-1> Marijuana Legalization Initiative, or Proposition 207, a ballot initiative which would legalize cannabis for recreational use and possession. If passed, individuals in Arizona could legally grow up to six cannabis plants on or in their residences. The bill would not, however, allow residents to grow or use cannabis in public view. This initiative would give the ADHS the responsibility of regulating recreational cannabis. If passed, the ADHS would begin licensing dispensaries by accepting applications for licensing for-profit recreational cannabis dispensaries. Applications from existing nonprofit medical cannabis dispensaries would be reviewed first, with these dispensaries being allowed to simultaneously hold nonprofit and for-profit licenses. Applications from areas without existing dispensaries would also be prioritized. The law seeks to address historical inequities surrounding cannabis laws. Specifically, the law would create a Social Equity Owner Program to provide licenses to entities with owners "from communities disproportionately impacted by the enforcement of previous marijuana laws." Additionally, the law would allow people to petition for the expungement of certain cannabis-related convictions from their record. The Marijuana Legalization Initiative would institute a 16% tax on the sale of cannabis on top of existing Arizona sales taxes. If passed, the law would also give local governments authority, such as the ability to ban cannabis facilities and control over elements of zoning and licensing. Prospects for passage of Marijuana Legalization Initiative (2020) Proposition 207 The prospects for passage of Proposition 207 are uncertain. In 2016, Arizona failed to pass a <https://ballotpedia.org/Arizona_Marijuana_Legalization,_Proposition_205_(20 16)> bill that would have legalized cannabis, with 51% of voters opposed. Polls suggest that the majority of Arizonians support the 2020 Marijuana Legalization Initiative. According to a June <https://ohpredictive.com/press-releases/az-opposition-to-marijuana/> poll, 62% of voters expressed that they would support the measure. However, the most recent <https://www.monmouth.edu/polling-institute/reports/monmouthpoll_az_091720/> poll in September found the margin to be a lot closer, with 51% polled in favor and 41% against, and the margin shrinking even further when considering the likelihood of voter turnout (but with support still in the majority). Therefore, it seems likely this bill will pass but it may come down to which Arizonians turn out to vote. MJ Biz Daily-Pascal-" <https://mjbizdaily.com/medical-cannabis-in-europe-the-markets-and-opportuni ties-2nd-edition/> Medical Cannabis in Europe: The Markets & Opportunities." Europe's legal medical cannabis market might one day eclipse North America's, but in 2019 the market was worth roughly 240 million euros ($260 million) - meaning the continent is still far from reaching its potential. That is one of the critical takeaways from Marijuana Business Daily's updated - and free - report, " <https://mjbizdaily.com/medical-cannabis-in-europe-the-markets-and-opportuni ties-2nd-edition/> Medical Cannabis in Europe: The Markets & Opportunities." "This report provides industry leaders and investors interested in the European markets with a realistic estimate of current market sizes and a detailed analysis of the countries where the most opportunities exist," wrote the author of the report, MJBizDaily International Analyst Alfredo Pascual. Pascual believes executives will benefit from an honest picture of the market as it exists today, instead of relying mostly on wildly speculative projections of what could occur years into the future. "Most cannabis companies don't have years of cash available to spend without generating much revenue until those future multibillion markets materialize," he said in an interview. "While the long-term expectation of Europe being a massive medical - and, eventually, recreational - cannabis industry continues to show promise, this report highlights the reality of the market today, including the actual sales and the regulatory frameworks that exist in the main European markets," Pascual wrote in the report. "Medical Cannabis in Europe" lends credence to executives who are growing their businesses as the European market evolves. That is another critical takeaway from the report, Pascual said. "Businesses can only operate within the boundaries of a jurisdiction's laws and regulations," he said. "In many cases in Europe, those laws and regulations are in an infantile stage. "The risk some businesses face is they're building facilities before laws and regulations are clear and before functional markets develop." Marijuana Business Daily estimates total sales of medical cannabis in Europe in 2019 ranged from 230 million to 250 million euros, with the report noting that accurate estimates are complex because of a lack of official data in several of the main markets and no harmonized definitions of medical cannabis across the continent. Roughly half the retail value was accounted for in the markup that pharmacies add before dispensing the products in countries such as Germany and Italy. More takeaways from "Medical Cannabis in Europe": * 2019 was a good year for the largest markets - Germany and Italy - with double-digit growth over 2018. But all other medical cannabis programs on the continent either didn't grow much (the Netherlands) or grew meaningfully albeit from a tiny starting point (Czech Republic). * Corporate expectations that sales will grow exponentially after medical cannabis is legalized is wishful thinking. Irregular growth is common. An example is <https://mjbizdaily.com/danish-medical-cannabis-scheme-ends-2019-on-low-note /> Denmark. * Isolated cannabinoids are an important product category in Europe, representing about 30% of reimbursed sales in Germany and the vast majority of sales in Austria. Possibly the largest acquisition of a European cannabis company to date was when Canada's Canopy Growth <https://mjbizdaily.com/canopy-acquire-german-cannabis-company-c3-250-millio n/> purchased C3 in 2019, becoming a regional leader in the category of isolated THC. * Many countries and entrepreneurs want to export to Germany, but products sold in Germany still come from only a few producers that are able to comply with stringent quality requirements. Not many companies were added to that list in 2019 compared to 2018. And some companies, such as Alberta-based Aurora Cannabis, <https://mjbizdaily.com/aurora-cannabis-to-resume-medical-marijuana-sales-in -germany/> struggled to comply with the rules last year. * Supply issues aren't such a big issue anymore. For example, as of the release of the report, at least 30 different flower varieties were in stock in Germany. Variety for other product types, such as full-spectrum extracts, has room for improvement. The report acknowledges specific supply issues throughout 2019 in different European countries. * Though adult-use cannabis is not the focus, the report notes that 2019 was largely uneventful when it comes to recreational legalization in Europe. Luxembourg did not take a meaningful legislative step after the announcement of the intention to legalize at the end of 2018. Switzerland has a pilot project in the works, but it remains far from materializing. The Netherlands advanced its recreational pilot project, but it is limited to only a few, small municipalities. |
AuthorArchivesCategoriesCopyright © 2020 CIHG INC
|
RSS Feed
